Ignite Creation Date:
2025-12-25 @ 2:07 AM
Ignite Modification Date:
2026-01-25 @ 6:45 AM
Study NCT ID:
NCT00297960
Status:
COMPLETED
Last Update Posted:
2006-10-18
First Post:
2006-02-28
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Influence of Treatment With Olanzapine or Ziprasidone on Transcapillary Glucose Transport in Human Skeletal Muscle
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'C092292', 'term': 'ziprasidone'}, {'id': 'D000077152', 'term': 'Olanzapine'}, {'id': 'D017551', 'term': 'Microdialysis'}], 'ancestors': [{'id': 'D001569', 'term': 'Benzodiazepines'}, {'id': 'D001552', 'term': 'Benzazepines'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D003956', 'term': 'Dialysis'}, {'id': 'D002623', 'term': 'Chemistry Techniques, Analytical'}, {'id': 'D008919', 'term': 'Investigative Techniques'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'interventionModel': 'PARALLEL'}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2005-04'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2005-10', 'lastUpdateSubmitDate': '2006-10-17', 'studyFirstSubmitDate': '2006-02-28', 'studyFirstSubmitQcDate': '2006-02-28', 'lastUpdatePostDateStruct': {'date': '2006-10-18', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2006-03-01', 'type': 'ESTIMATED'}}, 'conditionsModule': {'conditions': ['Healthy Male Volunteers']}, 'referencesModule': {'references': [{'pmid': '11926934', 'type': 'BACKGROUND', 'citation': 'Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, Selke G. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry. 2002 Apr;59(4):337-45. doi: 10.1001/archpsyc.59.4.337.'}, {'pmid': '9703331', 'type': 'BACKGROUND', 'citation': 'Rosdahl H, Lind L, Millgard J, Lithell H, Ungerstedt U, Henriksson J. Effect of physiological hyperinsulinemia on blood flow and interstitial glucose concentration in human skeletal muscle and adipose tissue studied by microdialysis. Diabetes. 1998 Aug;47(8):1296-301. doi: 10.2337/diab.47.8.1296.'}, {'pmid': '8997218', 'type': 'BACKGROUND', 'citation': 'Muller M, Holmang A, Andersson OK, Eichler HG, Lonnroth P. Measurement of interstitial muscle glucose and lactate concentrations during an oral glucose tolerance test. Am J Physiol. 1996 Dec;271(6 Pt 1):E1003-7. doi: 10.1152/ajpendo.1996.271.6.E1003.'}]}, 'descriptionModule': {'briefSummary': 'Healthy volunteers will undergo euglycaemic hyperinsulinaemic clamp and microdialysis before and after administration of 10mg olanzapine or 80mg ziprasidone during 10 days.', 'detailedDescription': 'Background:\n\nThe efficacy of atypical antipsychotics, such as olanzapine, clozapine, risperidone, quetiapine and ziprasidone in treating a broad spectrum of symptoms in schizophrenia as well as their lower likelihood of extrapyramidal symptoms have led to an increased use of these substances. However there is an ongoing debate whether treatment with atypical antipsychotics is associated with a higher risk for metabolic abnormalities. The FDA stated in 2003 that all atypical antipsychotics increase the risk for glucose abnormalities. For olanzapine many, but not all studies report an increased risk for the development of metabolic abnormalities, such as glucose intolerance, insulin-resistance and consequentially NIDDM (Non-Insulin-Dependent-Diabetes Mellitus). Ziprasidone on the other hand seems to be associated with a more favorable metabolic safety profile.Glucose intolerance and insulin resistance being risk factors for the development of NIDDM and cardiovascular disease, the exact determination of putative effects of atypical antipsychotics on insulin sensitivity and resistance is of great need. An innovative technique, microdialysis, allows for the measurement of various analytes in the interstitial space, i.e. to assess insulin sensitivity directly at the responsible compartment, which is the human skeletal muscle. With the use of microdialysis it is possible to determine the arterial to interstitial gradient, a suitable marker for plasma glucose extraction of peripheral tissue, and thus detect insulin resistance directly at the site of insulin action.\n\nAim of the study:\n\nTo compare the effects of treatment with the atypical antipsychotics olanzapine and ziprasidone in steady-state conditions on the arterial to interstitial skeletal muscle gradient for glucose in human skeletal muscle during euglycaemic hyperinsulinaemic clamp conditions in male healthy volunteers.\n\nStudy design:\n\nOpen, randomized, mono-center study.\n\nMaterials and methods:\n\nHealthy volunteers will undergo euglycaemic hyperinsulinaemic clamp and microdialysis before and after administration of 10mg olanzapine or 80mg ziprasidone during 10 days.\n\nStudy population:\n\n15 healthy volunteers will participate in each arm of the study, summing up to a total of 30 participants.\n\nMain outcome variable:\n\nThe arterial to interstitial skeletal muscle glucose gradient before and during euglycaemic hyperinsulinaemic clamp conditions, before and after administration of 10mg olanzapine or 80mg ziprasidone under steady-state conditions.'}, 'eligibilityModule': {'sex': 'MALE', 'stdAges': ['ADULT'], 'maximumAge': '55 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Age between 18-55\n* Healthy male volunteers\n* No history of drug or alcohol abuse\n* No regular nicotine consumption at time of enrollment\n* Physical activity at least twice a week\n* Body mass Index between 19-24 kg/m2\n* Normal laboratory values\n* Normotension (blood pressure less than 140/90)\n* No past or present history of psychiatric disorder\n* No family history of diabetes or obesity\n* Written informed consent\n\nExclusion Criteria:\n\n* Use of medication within the last 14 days\n* Consumption of alcohol within the last 5 days\n* Family history of diabetes or obesity\n* Past or present psychiatric disorder'}, 'identificationModule': {'nctId': 'NCT00297960', 'briefTitle': 'Influence of Treatment With Olanzapine or Ziprasidone on Transcapillary Glucose Transport in Human Skeletal Muscle', 'organization': {'class': 'OTHER', 'fullName': 'Medical University of Vienna'}, 'officialTitle': 'Influence of Treatment With Olanzapine or Ziprasidone on Transcapillary Glucose Transport in Human Skeletal Muscle', 'orgStudyIdInfo': {'id': 'olanz/zipra'}, 'secondaryIdInfos': [{'id': 'EUDRACT Nr.: 2004-002147-27'}]}, 'armsInterventionsModule': {'interventions': [{'name': 'ziprasidone or olanzapine', 'type': 'DRUG'}, {'name': 'hyperinsulinaemic euglycaemic clamp', 'type': 'PROCEDURE'}, {'name': 'microdialysis (skeletal muscle)', 'type': 'PROCEDURE'}]}, 'contactsLocationsModule': {'locations': [{'zip': '1090', 'city': 'Vienna', 'country': 'Austria', 'facility': 'Department of Clinical Pharmacology, Medical University Vienna', 'geoPoint': {'lat': 48.20849, 'lon': 16.37208}}], 'overallOfficials': [{'name': 'Siegfried Kasper, Prof. MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Medical University Vienna, Department of General Psychiatry'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Medical University of Vienna', 'class': 'OTHER'}}}}